En direct

Le Centre de Recherche en Cancérologie de Marseille fête ses 50 ans ! -

03 2022 Current oncology (Toronto, Ont.)

Repeated Multimodality Ablative Therapies for Oligorecurrent Pulmonary Metastatic Disease.


Macagno A, de Nonneville A, Annede P, Piana G, Pougnet I, Daidj N, Moureau-Zabotto L, Darreon J, Padovani L, Bertucci F, Salem N


Stereotactic body radiotherapy (SBRT) and percutaneous thermal ablation (TA) are alternatives to surgery for the management of pulmonary oligometastases. In this collaborative work, we retrospectively analyzed patients who had undergone iterative focal ablative treatments of pulmonary oligometastases. We hypothesized that repeated ablative therapies could benefit patients with consecutive oligometastatic relapses. Patients treated with SBRT and/or TA for pulmonary oligometastases in two French academic centers between October 2011 and November 2016 were included. A total of 102 patients with 198 lesions were included; 45 patients (44.1%) received repeated focal treatments at the pulmonary site for an oligorecurrent disease (the « multiple courses » group). Median follow-up was 22.5 months. The 3-year overall survival rates of patients who had a single treatment sequence (the « single course » group) versus the « multiple courses » were 73.9% and 78.8%, respectively, which was not a statistically significant difference ( = 0.860). The 3-year systemic therapy-free survival tended to be longer in the « multiple courses » group (50.4%) than in the « single course » group (44.7%) ( = 0.081). Tolerance of repeated treatments was excellent with only one grade 4 toxicity. Thereby, multimodality repeated ablative therapy is effective in patients with pulmonary oligorecurrent metastases. This strategy may delay the use of more toxic systemic therapy.

Lire l‘article